Cagent Vascular Launches Serranator SL-Pro for Chronic Limb-Threatening Ischemia and Pedal Disease

February 3, 2025—Cagent Vascular, Inc. announced the launch of its Serranator SL-Pro percutaneous transluminal angioplasty (PTA) serration balloon catheter. Cagent developed serration technology for vessel dilation in endovascular interventions.

According to the company, Serranator SL-Pro is purpose-built for pedal intervention as well as challenging-to-cross tibial disease. The device utilizes Cagent’s serration technology on a redesigned platform for improved deliverability and trackability.

Cagent Vascular stated that the Serranator and Serranator SL-Pro PTA serration balloon catheters, which are FDA cleared, use the company’s stainless steel microserration technology that is designed to create linear, interrupted scoring along the endoluminal surface.

The company added that the technology provides 1,000-times more point force compared with plain-old balloon angioplasty. Serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies.

Michael Lichtenberg, MD, who is Chief Medical Officer and Director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany, discussed the device in the company’s press release.

“As an experienced Serranator operator, my team has grown accustomed to the benefits of serration, including great lumen gain; low complication rate; and low 6% BTK vessel recoil versus 55% measured recoil with plain balloon,” commented Dr. Lichtenberg. “We also appreciate Serranator’s ability to safely and effectively treat complex disease, even down into the pedal arteries. With SL-Pro, we’re eager to experience the advantages of serranation in this new, more deliverable platform.”